Table 1 Patient Demographics and Baseline Characteristics
Characteristic | Former placebo patientsa (N = 88) | Former GXR patientsa (N = 62) | New patients (N = 41) | All patients (N = 191) |
|---|---|---|---|---|
Male, n (%) | 56 (63.6) | 47 (75.8) | 27 (65.9) | 130 (68.1) |
Age, y, mean (SD) | 34.2 (10.1) | 30.6 (8.2) | 34.3 (9.2) | 33.1 (9.4) |
<30 y, n (%) | 32 (36.4) | 32 (51.6) | 15 (36.6) | 79 (41.4) |
30 to <40 y, n (%) | 31 (35.2) | 18 (29.0) | 13 (31.7) | 62 (32.5) |
≥40 y, n (%) | 25 (28.4) | 12 (19.4) | 13 (31.7) | 50 (26.2) |
Previous disease recorded in medical history, yes, n (%) | 46 (52.3) | 29 (46.8) | 16 (39.0) | 91 (47.6) |
Prior ADHD medicationb, yes, n (%) | 42 (47.7) | 30 (48.4) | 19 (46.3) | 91 (47.6) |
Atomoxetine | 24 (27.3) | 15 (24.2) | 11 (26.8) | 50 (26.2) |
Methylphenidate | 22 (25.0) | 15 (24.2) | 10 (24.4) | 47 (24.6) |
Other | 0 | 3 (4.8) | 0 | 3 (1.6) |
ADHD presentation, n (%) | ||||
Combined presentation | 46 (52.3) | 31 (50.0) | 20 (48.8) | 97 (50.8) |
Predominantly inattentive presentation | 40 (45.5) | 29 (46.8) | 21 (51.2) | 90 (47.1) |
Predominantly hyperactive-impulsive presentation | 2 (2.3) | 2 (3.2) | 0 | 4 (2.1) |
Baseline ADHD-RS-IV total score, mean (SD) | 32 (7.1) | 31.7 (6.0) | 32.8 (5.9) | 32.1 (6.5) |
<30, n (%) | 41 (46.6) | 30 (48.4) | 12 (29.3) | 83 (42.5) |
≥30, n (%) | 47 (53.4) | 32 (51.6) | 29 (70.7) | 108 (56.5) |